Amarin Corporation plc (AMRN) Financial Analysis & Valuation | Quarter Chart
Amarin Corporation plc (AMRN)
AMRNPrice: $14.52
Fair Value: 🔒
🔒score
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty... more
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization o... more
Description
Shares
| Market Cap | $300.31M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | IE | CEO | Aaron D. Berg |
| IPO Date | 1993-04-01 | CAGR | 0.09% |
| Employees | 275 | Website | www.amarincorp.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
AMRN chart loading...
Fundamentals
Technicals
| Enterprise Value | $175.29M | P/E Ratio | — |
| Forward P/E | 16.13 | PEG Ratio | — |
| P/S Ratio | 1.4 | P/B Ratio | 0.67 |
| P/CF Ratio | 11.84 | P/FCF Ratio | 11.77 |
| EPS | $-1.6 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 0.33% | Gross Margin | 0.52% |
| Operating Margin | -0.17% | Profit Margin | -0.16% |
| ROE | -0.07% | ROA | -0.05% |
| ROCE | -0.08% | Current Ratio | 3.48 |
| Quick Ratio | 2.46 | Cash Ratio | 0.73 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | -1.68 | Piotroski Score | 4 |